JP2020530437A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530437A5
JP2020530437A5 JP2019570982A JP2019570982A JP2020530437A5 JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5 JP 2019570982 A JP2019570982 A JP 2019570982A JP 2019570982 A JP2019570982 A JP 2019570982A JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5
Authority
JP
Japan
Prior art keywords
neopeptides
recombinant poxvirus
neopeptide
tumor
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019570982A
Other languages
English (en)
Japanese (ja)
Other versions
JP7334124B2 (ja
JP2020530437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/066668 external-priority patent/WO2018234506A2/en
Publication of JP2020530437A publication Critical patent/JP2020530437A/ja
Priority to JP2023100296A priority Critical patent/JP2023123609A/ja
Publication of JP2020530437A5 publication Critical patent/JP2020530437A5/ja
Application granted granted Critical
Publication of JP7334124B2 publication Critical patent/JP7334124B2/ja
Priority to JP2025121773A priority patent/JP2025160281A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570982A 2017-06-21 2018-06-21 個別化ワクチン Active JP7334124B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023100296A JP2023123609A (ja) 2017-06-21 2023-06-19 個別化ワクチン
JP2025121773A JP2025160281A (ja) 2017-06-21 2025-07-18 個別化ワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17305760 2017-06-21
EP17305760.5 2017-06-21
EP18305496.4 2018-04-23
EP18305496 2018-04-23
PCT/EP2018/066668 WO2018234506A2 (en) 2017-06-21 2018-06-21 PERSONALIZED VACCINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023100296A Division JP2023123609A (ja) 2017-06-21 2023-06-19 個別化ワクチン

Publications (3)

Publication Number Publication Date
JP2020530437A JP2020530437A (ja) 2020-10-22
JP2020530437A5 true JP2020530437A5 (cg-RX-API-DMAC7.html) 2023-07-05
JP7334124B2 JP7334124B2 (ja) 2023-08-28

Family

ID=62599637

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570982A Active JP7334124B2 (ja) 2017-06-21 2018-06-21 個別化ワクチン
JP2023100296A Pending JP2023123609A (ja) 2017-06-21 2023-06-19 個別化ワクチン
JP2025121773A Pending JP2025160281A (ja) 2017-06-21 2025-07-18 個別化ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023100296A Pending JP2023123609A (ja) 2017-06-21 2023-06-19 個別化ワクチン
JP2025121773A Pending JP2025160281A (ja) 2017-06-21 2025-07-18 個別化ワクチン

Country Status (10)

Country Link
US (3) US11969462B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641803A2 (cg-RX-API-DMAC7.html)
JP (3) JP7334124B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240113607A (cg-RX-API-DMAC7.html)
CN (1) CN111065406A (cg-RX-API-DMAC7.html)
AU (1) AU2018287159B2 (cg-RX-API-DMAC7.html)
CA (1) CA3067405A1 (cg-RX-API-DMAC7.html)
IL (1) IL271558B2 (cg-RX-API-DMAC7.html)
SG (1) SG11201912429RA (cg-RX-API-DMAC7.html)
WO (1) WO2018234506A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
JP7894215B2 (ja) * 2019-01-03 2026-07-23 エヴァクシオン・アクシェセルスケープ ネオエピトープを標的とするワクチン
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113631185A (zh) * 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
MX2022002417A (es) * 2019-08-29 2022-03-22 Astellas Pharma Inc Virus vaccinia oncoliticos modificados geneticamente y metodos de uso de los mismos.
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
CN111303277A (zh) * 2020-02-19 2020-06-19 中国人民解放军军事科学院军事医学研究院 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12
CN115927215B (zh) * 2023-01-18 2025-10-17 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN116656730B (zh) * 2023-05-25 2024-03-19 军事科学院军事医学研究院军事兽医研究所 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
WO2026044351A1 (en) * 2024-08-28 2026-03-05 The Council Of The Queensland Institute Of Medical Research Hpv antigenic composition and uses thereof
WO2026108904A1 (zh) * 2024-11-21 2026-05-28 北京立康生命科技有限公司 一种间隔肽及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
US7094412B2 (en) 2001-12-10 2006-08-22 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
KR101121971B1 (ko) 2003-07-22 2012-03-09 비바리스 부착성 또는 비부착성 조류 세포주를 이용한폭스바이러스의 생산
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
ATE477321T1 (de) 2006-01-05 2010-08-15 Transgene Sa Aviäre telomerase reverse transkriptase
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
CA2687304A1 (en) 2007-05-15 2008-11-20 Transgene S.A. Signaling peptides
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
EP2212423B1 (en) 2007-11-19 2015-02-11 Transgene SA Poxviral oncolytic vectors
DK2212345T3 (en) 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors
AU2009214768B2 (en) 2008-02-12 2015-01-22 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
EP2199400A1 (en) * 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
KR102022952B1 (ko) 2011-08-05 2019-09-20 신라젠(주) 백시니아 바이러스의 생산을 위한 방법 및 조성물
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US20160032396A1 (en) * 2013-03-15 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Identification and Use of Circulating Nucleic Acid Tumor Markers
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
JP6740127B2 (ja) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
DK3142690T3 (da) 2014-05-13 2022-05-09 Bavarian Nordic As Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
TW201708536A (zh) 2015-05-26 2017-03-01 艾法西斯公司 個人化的基於遞送載體之免疫療法及其用途
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3313975A4 (en) 2015-06-24 2019-03-13 Advaxis, Inc. MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY
JP7114477B2 (ja) * 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines

Similar Documents

Publication Publication Date Title
KR102021585B1 (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
JP7486206B2 (ja) 人工的に構築されたrna編集酵素による部位特異的rna編集および関連使用
JP5474816B2 (ja) mRNA翻訳エンハンサーエレメントに関する組成物および方法
CN108251452A (zh) 一种表达Cas9基因的转基因斑马鱼及其构建方法和应用
CA2983364A1 (en) Compositions and methods for the treatment of nucleotide repeat expansion disorders
JP2018532419A (ja) CRISPR−Cas sgRNAライブラリー
CN113227387B (zh) 基于单细胞转录组开发aav载体和启动子的方法和材料
US6395872B1 (en) Secreted neural adhesion proteins
JP2005522225A (ja) 亢進された遺伝子発現系
JPH07265085A (ja) 組換えポックスウイルス
CN117859703B (zh) Anxa11基因的新突变致病位点C104G的敲入小鼠模型及其构建方法与应用
CN110885799A (zh) 一种基于腺病毒的基因编辑方法
CN112899237A (zh) Cdkn1a基因报告细胞系及其构建方法和应用
US9765305B2 (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
CA3109429A1 (en) Methods and compositions for producing a virus
CN121548639A (zh) 用于crispr干扰和激活的改进方法和组合物
KR101613457B1 (ko) 고추 식물 유래 신규한 고추 난쟁이 엔도르나바이러스 유전자
KR940001265B1 (ko) 프로모터, 그를 함유하는 플라스미드 및 재조합 아비폭스비루스
US6841347B1 (en) In vivo construction of DNA libraries
KR102955030B1 (ko) 신규한 가이드 rna 및 이의 용도
CN119506355B (zh) 一种用于重组痘病毒包装的载体系统及其应用
JP7034818B2 (ja) 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法
WO2009144958A1 (ja) 組換えウイルス、これを保持する大腸菌およびその製造法
RU2020101489A (ru) Персонализированная вакцина
Gite et al. 35 Protein Truncation